InvestorsHub Logo
Followers 22
Posts 7075
Boards Moderated 0
Alias Born 05/14/2011

Re: None

Tuesday, 09/15/2020 6:41:57 PM

Tuesday, September 15, 2020 6:41:57 PM

Post# of 58917
You all made it in two published fact sheets today. Not banner busting, but progress

Coronavirus (COVID-19) Update: FDA Publishes Comparative Performance Data for COVID-19 Molecular Diagnostic Tests..Link to full document

Where you'll find
SARS-CoV-2 Reference Panel Comparative Data
Table 1. Status of Developers of Authorized EUAs Contacted for distribution of the FDA SARS-CoV-2 Reference Panel*


Developer Authorized Test Status**


scroll down to
Applied DNA Sciences, Inc. Linea COVID-19 Assay Kit Results in Table 2A

Dunno what is listed on Table 2A.Second reference is inferred within this PR: TYME’s Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published ...

......From the initial diagnoses of PSA rise, 100% of patients (23/23) remained free of metastatic progression (MFS) and 87% of patients (20/23) have maintained radiographic progression-free survival (rPFS) with a median duration of therapy of 6.5 months since starting SM-88 treatment. All patients who have maintained meaningful reductions in circulating tumor cells (CTCs) on SM-88 were 100% free of any radiographic progression.



Alrighty. GLTA



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APDN News